TNDM — Tandem Diabetes Care, Inc.

Tandem Diabetes Care (TNDM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Record Sales: Tandem achieved over $1 billion in sales for 2025, with Q4 sales reaching $290 million, a 15% year-over-year increase.
• U.S. Sales: Q4 U.S. sales grew 14% to $210 million, driven by over 27,000 pump shipments, marking the highest quarterly achievement.
• International Sales: Q4 international sales increased 17% to $80 million.
• Gross Margin: Full-year gross margin improved to 54%, with Q4 gross margin at 58%.
• Adjusted EBITDA: Q4 adjusted EBITDA was 11% of sales, a significant improvement from the prior year.
• Operating Margin: Positive operating margin of 3% in Q4, marking the first positive operating margin since 2021.
• Cash Position: Exited 2025 with nearly $300 million in cash and investments.

2. Strategic Updates and Business Highlights

• Commercial Operations Modernization: Expanded U.S. sales team and began direct operations in the U.K., Switzerland, and Austria, enhancing international sales capabilities.
• Product Innovations: Launched Control-IQ+ and introduced new features like FreeStyle Libre 3 Plus and Android Control for Mobi. Upcoming launches include Mobi Tubeless and additional integrations.
• Pharmacy Strategy: Transitioning to a pay-as-you-go (PayGo) reimbursement model to enhance customer access and reduce upfront costs, expected to drive long-term growth.
• Focus on Type 2 Diabetes: Expanded market reach with new technology aimed at type 2 diabetes patients, doubling the addressable market.

3. Forward Guidance and Outlook

• 2026 Sales Expectations: Projected U.S. sales between $730 million to $745 million, with growth in pump shipments of 10% to 11%. International sales expected to be $335 million to $340 million.
• Overall 2026 Guidance: Worldwide sales anticipated between $1.065 billion to $1.085 billion, incorporating headwinds from the PayGo transition.
• Margin Projections: Gross margin expected to improve to 56% to 57%, with adjusted EBITDA projected at 5% to 6% for the full year.

4. Bad News, Challenges, or Points of Concern

• Transition Headwinds: The shift to the PayGo model is expected to create revenue headwinds in 2026, estimated at $70 million to $80 million, impacting the recognition of sales.
• Market Transition Risks: The transition to direct operations in international markets may face challenges, and the full benefits of pricing increases may not be realized immediately.
• Dependence on Renewals: Concerns about potential declines in renewal shipments in 2027 due to the historical drop-off in new patient starts, although management remains confident in growth from existing customers and pharmacy transitions.

5. Notable Q&A Insights

• Confidence in Growth: Management emphasized that the PayGo model will significantly enhance customer retention and reduce barriers to entry, which should drive new patient starts.
• Pharmacy Channel Strategy: The transition to pharmacy is expected to improve patient access and reduce out-of-pocket costs, with a goal of 20% of pump shipments through pharmacy by the end of 2026.
• International Operations: Direct operations in new markets are progressing well, with expectations to scale up sales productivity throughout 2026.
• C-peptide Testing Impact: New ADA guidelines on C-peptide testing could enhance discussions with CMS and potentially increase access for type 2 diabetes patients.

Overall, Tandem Diabetes Care is positioned for growth in 2026, despite facing challenges related to its strategic transition to a new business model and the impacts of market dynamics.